HRT and cardiovascular events

Study had insufficient power to investigate safety

BMJ 2012; 345 doi: http://dx.doi.org/10.1136/bmj.e8146 (Published 3 December 2012)
Cite this as: BMJ 2012;345:e8146

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Jacques E Rossouw, medical officer1,
  2. JoAnn E Manson, professor of medicine2,
  3. Andrew M Kaunitz, professor of obstetrics and gynecology3,
  4. Marcia L Stefanick, professor of medicine4
  1. 1National Heart, Lung, and Blood Institute, Bethesda, MD, USA
  2. 2Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA
  3. 3University of Florida College of Medicine-Jacksonville, FL, USA
  4. 4Stanford University School of Medicine, Stanford, CA, USA
  1. rossouwj{at}nih.gov

There are several concerns about the robustness of Schierbeck and colleagues’ findings.1 The open label design means that the trial could not control for placebo effect, and knowledge of active treatment could have led to differential ascertainment of outcomes.

The composite outcome of mortality, myocardial infarction, and heart failure was not prespecified in the design paper, …

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Article access

Article access for 1 day

Purchase this article for £20 $30 €32*

The PDF version can be downloaded as your personal record

* Prices do not include VAT

THIS WEEK'S POLL